Form 8-K Theravance Biopharma, For: Feb 27

Go back to Form 8-K Theravance Biopharma, For: Feb 27

Theravance Biopharma (TBPH) Misses Q4 EPS by 31c

February 27, 2017 4:09 PM EST

Theravance Biopharma (NASDAQ: TBPH) reported Q4 EPS of ($1.36), $0.31 worse than the analyst estimate of ($1.05). Revenue for the quarter came in at $5.7 million versus the consensus estimate of $4.9 million.

Outlook

We expect to fund advancements across all stages of our development pipeline, including investment towards... More